Myofibroblastic Proliferation as a Secondary Malignancy From Radioactive Iodine Treatment for Thyroid Carcinoma: A Case Report

甲状腺癌放射性碘治疗后继发性恶性肿瘤——肌纤维母细胞增生:病例报告

阅读:2

Abstract

Thyroid carcinoma is an important health issue having significant morbidity and mortality. Management includes thyroidectomy followed by radioactive iodine ablation to kill any remaining tumor cells. However, the use of radioactive iodine ablation (RAI) is not without risks; one such risk is the development of secondary cancers, especially in patients undergoing radioactive iodine ablation at a younger age. We present a case of thyroid carcinoma where the patient was treated with radioactive iodine ablation over 20 years ago. The patient was recently found to have a neck mass, which was investigated with imaging and biopsied. Pathological findings were consistent with myofibroblastic proliferation, which is a benign abnormal growth of myofibroblasts but has small potential for malignant transformation. Management generally involves surgical excision, and other treatments like steroids, non-steroidal anti-inflammatory drugs, and radiation therapy can be used in select cases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。